Janet E. Rush, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Lindheimer and Barron (1) have described the potential risk to the fetus exposed to angiotensin-converting enzyme (ACE) inhibitors in utero. As a result of reports of the development of renal impairment in neonates who had been exposed in utero to enalapril, Merck Sharpe & Dohme has been working with the Food and Drug Administration to develop labeling that would appropriately describe the potential risk. I am pleased to report that language has been developed and is expected to be incorporated into all package circulars for ACE-inhibitors as quickly as possible.
Rush JE. Enalapril, Pregnancy, and Package Circulars. Ann Intern Med. ;109:926–927. doi: 10.7326/0003-4819-109-11-926
Download citation file:
Published: Ann Intern Med. 1988;109(11):926-927.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use